• Home
  • NEW DAY MEDICINE
  • 10 (60) 2023
  • 167 -10 (60) 2023 — Е.V. Boyko, J.M.Iskandarov — MODELING OF A PROGNOSTIC PROGRAM FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER

167 -10 (60) 2023 — Е.V. Boyko, J.M.Iskandarov — MODELING OF A PROGNOSTIC PROGRAM FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER

MODELING OF A PROGNOSTIC PROGRAM FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER

Е.V. Boyko, Republic of specialized oncology and radiology Scientific and practical medical center

J.M.Iskandarov, Bukhara branch of RSNPMTSOiR, Uzbekistan

I.M. Iskandarova, ³Bukhara State Medical Institute named after Abu Ali ibn Sina

Sh.T. Xasanov Republic of specialized oncology and radiology Scientific and practical medical center

Resume

A number of scientific studies are being conducted around the world in the field of diagnosis and treatment of prostate cancer, which include: determining the timing of the onset of hormone resistance of prostate cancer after treatment depending on the severity of prognosis factors, studying the intensity of development of hormone resistance of prostate cancer depending on the main course of treatment, studying the effectiveness of targeted hormone therapy with abiraterone in the treatment of prostate cancer, analysis of the results of treatment with taxane chemotherapy for castration-resistant prostate cancer, development of an algorithm for the treatment of castration-resistant prostate cancer depending on the receptor status of the tumor and prognosis factors. All of the above is a prerequisite for the development of prognostic criteria for the development of hormonal resistance, as well as treatment algorithms for castration-resistant prostate cancer.

Key words: prostate cancer, castration-resistant prostate cancer, prognostic program.

First page

973

Last page

977

For citation: Е.V.Boyko,J.M.Iskandarov, I.M.Iskandarova, Sh.T.Xasanov – MODELING OF A PROGNOSTIC PROGRAM FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER //New Day in Medicine 2023 10(60): 973-977 https://newdaymedicine.com/index.php/2023/12/28/l-725/

LIST OF REFERENCES:

  1. Tillyashaykhov M.N., Djanklich S.M., Ibragimov S.N., Imamov O.A.
    Analysis of cancer incidence structure in the Republic of Uzbekistan. // Онкология и радиология Казахстана, 2021;61(3):4-8.
  2. Rawla P. Epidemiology of Prostate Cancer. // World J Oncol. Apr;2019;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20. PMID: 31068988; PMCID: PMC6497009.
  3. Reichert Z.R., Hussain M. Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer. // Cancer J. 2016 Sep-Oct;22(5):326-329. doi: 10.1097/PPO.0000000000000214. PMID: 277493 Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. PMID: 23859952.
  4. Shang S, Hua F, Hu ZW. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017 May 16;8(20):33972-33989. doi: 10.18632/oncotarget.15687. PMID: 28430641; PMCID: PMC5464927.
  5. Shevach J, Weiner A, Morgans AK. Quality of Life-Focused Decision-Making for Prostate Cancer. // Curr Urol Rep. 2019 Aug 29;20(10):57. doi: 10.1007/s11934-019-0924-2. PMID: 31468212.
  6. Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. // Lancet Oncol. 2016 Feb;17(2):153-163. doi: 10.1016/S1470-2045(15)00518-5. Epub 2016 Jan 14. PMID: 26774508.
  7. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. // Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25. PMID: 21353695; PMCID: PMC3090685.
  8. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. // Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. PMID: 22995653.
  9. Yang TK, Chuang PC, Yen AM, Chen HH, Chen SL. Gene‒Prostate-Specific-Antigen-Guided Personalized Screening for Prostate Cancer. // Genes (Basel). 2019 Aug 24;10(9):641. doi: 10.3390/genes10090641. PMID: 31450602; PMCID: PMC6770934.
  10. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. // Cell Res. 2005 Jan;15(1):57-62. doi: 10.1038/sj.cr.7290266. PMID: 15686629.
  11. Zelic R, Fiano V, Grasso C, Zugna D, Pettersson A, Gillio-Tos A, Merletti F, Richiardi L. Global DNA hypomethylation in prostate cancer development and progression: a systematic review. // Prostate Cancer Prostatic Dis. 2015 Mar;18(1):1-12. doi: 10.1038/pcan.2014.45. Epub 2014 Nov 11. PMID: 25384337.

file

download